Merck's Keytruda Data Brighten Picture For PD-1 Inhibitors In Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from the American Society of Hematology meeting suggest role for checkpoint inhibitors in hematology could extend past what looks like a sure thing in Hodgkin lymphoma, but it’s early days yet.
You may also be interested in...
Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity
In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.